Literature DB >> 1607654

Presentation of three different viral peptides, HTLV-1 Tax, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule.

U Utz1, S Koenig, J E Coligan, W E Biddison.   

Abstract

To determine whether similar or dissimilar molecular features of class I molecules are involved in the presentation of structurally distinct peptides, we have investigated the influence of different pockets of the HLA-A2.1 molecule on the presentation of three different viral peptides. HTLV-I Tax peptide 12-19, HCMV gB 619-628, and influenza M1 58-66 are minimal peptides that induce HLA-A2.1-restricted noncross-reactive CTL. A detailed analysis of the structural features of HLA-A2.1 that are involved in peptide presentation was undertaken using a panel of 11 HLA-A2 mutants with single amino acid substitutions within pockets present in the peptide binding site. Nine of the 11 mutants affected presentation of each of the three peptides, whereas the other two mutants had negative effects on presentation of only two of these viral peptides. These results indicate that common structural features in HLA-A2 determine the binding of different peptides, and help to provide a plausible explanation for how structurally diverse peptides bind to HLA-A2.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607654

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Identification and functional perspective of a novel HLA-A allele: A*0279.

Authors:  Fangfang Liu; Shan Wang; Yingjiang Ye; Huagang Zhang; Yu Zhang; Weifeng Chen
Journal:  Immunogenetics       Date:  2006-04-01       Impact factor: 2.846

2.  Roles of the six peptide-binding pockets of the HLA-A2 molecule in allorecognition by human cytotoxic T-cell clones.

Authors:  M Matsui; C E Hioe; J A Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

3.  Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation.

Authors:  Nanae Harashima; Ryuji Tanosaki; Yukiko Shimizu; Kiyoshi Kurihara; Takao Masuda; Jun Okamura; Mari Kannagi
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  Mechanisms of T-cell activation by human T-cell lymphotropic virus type I.

Authors:  P Höllsberg
Journal:  Microbiol Mol Biol Rev       Date:  1999-06       Impact factor: 11.056

Review 5.  Peptide binding to MHC class I molecules: implications for antigenic peptide prediction.

Authors:  K C Parker; M Shields; M DiBrino; A Brooks; J E Coligan
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

6.  Restoration of CTL recognition of a mutant FMP peptide by a compensatory change in HLA-A2.

Authors:  M Matsui; J A Frelinger
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

Review 7.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  Antigenic peptides containing large PEG loops designed to extend out of the HLA-A2 binding site form stable complexes with class I major histocompatibility complex molecules.

Authors:  M Bouvier; D C Wiley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

9.  Analysis of the T-cell receptor repertoire of human T-cell leukemia virus type 1 (HTLV-1) Tax-specific CD8+ cytotoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion.

Authors:  U Utz; D Banks; S Jacobson; W E Biddison
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously.

Authors:  C E Parker; S Nightingale; G P Taylor; J Weber; C R Bangham
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.